# SEC Form 3 FORM 3

# UNITED STATES SECURITIES AND EXCHANGE

COMMISSION

Washington, D.C. 20549

### **INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES**

OMB APPROVAL

3235-OMB Number: 0104

Estimated average burden hours per response: 0.5

| Filed pursuant to Section 16(a) of the Securities Exchange Act of 193 | 4 |
|-----------------------------------------------------------------------|---|
| or Section 30(h) of the Investment Company Act of 1940                |   |

| 1. Name and Address of Reporting Person <sup>*</sup><br>Robinson John Edward                                                        | Requiring                                                            | ate of Event<br>uiring Statement<br>nth/Day/Year)<br>31/2021 3. Issuer Name <b>and</b> Ticker or Trading Symbol<br><u>Cogent Biosciences, Inc.</u> [ COGT ] |                                                                                                                                  |                                    |                                                                                                                               |                                                                              |                                                                   |  |  |
|-------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------|------------------------------------|-------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------|-------------------------------------------------------------------|--|--|
| (Last)(First)(Middle)C/O COGENT BIOSCIENCES, INC.200 CAMBRIDGE PARK DRIVE,<br>SUITE 2500(Street)CAMBRIDGE MA02140(City)(State)(Zip) |                                                                      |                                                                                                                                                             | 4. Relationship of Reportir<br>Issuer<br>(Check all applicable)<br>Director<br>X Officer (give<br>title below)<br>Chief Scientif | 10% O<br>Other (<br>below)         | wner 6. li                                                                                                                    | d (Month/Day/<br>ndividual or Jo<br>eck Applicable<br>Form filed I<br>Person | int/Group Filing<br>Line)<br>by One Reporting<br>by More than One |  |  |
| Table I - Non-Derivative Securities Beneficially Owned                                                                              |                                                                      |                                                                                                                                                             |                                                                                                                                  |                                    |                                                                                                                               |                                                                              |                                                                   |  |  |
| 1. Title of Security (Instr. 4)                                                                                                     | (Instr. 4) 2. Amount of Securities<br>Beneficially Owned (Inst<br>4) |                                                                                                                                                             |                                                                                                                                  | Form: D<br>(D) or In               | 3. Ownership<br>Form: Direct<br>(D) or Indirect<br>(I) (Instr. 5)<br>4. Nature of Indirect Beneficial<br>Ownership (Instr. 5) |                                                                              |                                                                   |  |  |
| Table II - Derivative Securities Beneficially Owned   (e.g., puts, calls, warrants, options, convertible securities)                |                                                                      |                                                                                                                                                             |                                                                                                                                  |                                    |                                                                                                                               |                                                                              |                                                                   |  |  |
|                                                                                                                                     | Expiration Date Und                                                  |                                                                                                                                                             | Underlying Derivative Security<br>(Instr. 4)                                                                                     |                                    | 4.<br>Conversion<br>or Exercise                                                                                               | 5.<br>Ownership<br>Form:                                                     | 6. Nature of<br>Indirect Beneficial<br>Ownership (Instr.          |  |  |
| 1 1-                                                                                                                                | ate<br>xercisable                                                    | Expiration<br>Date                                                                                                                                          |                                                                                                                                  | Price of<br>Derivative<br>Security | Direct (D)<br>or Indirect<br>(I) (Instr. 5)                                                                                   | 5)                                                                           |                                                                   |  |  |
| Stock Option (Right to Buy)                                                                                                         | (1)                                                                  | 03/31/2031                                                                                                                                                  | Common Stock                                                                                                                     | 500,000                            | 8.78                                                                                                                          | D                                                                            |                                                                   |  |  |

#### **Explanation of Responses:**

1. This stock option shall vest over a four year period as follows: 1/4th of the option shall vest one year after the vesting start date; then 1/48th of the option shall vest monthly over the remaining three year period.

### **Remarks:**

Exhibit 24 - Power of Attorney

/s/ Ryan Murr, Attorney-

04/15/2021

\*\* Signature of Reporting Person

in-Fact

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

#### POWER OF ATTORNEY

Know all by these presents that the undersigned hereby constitutes and appoints each of Ryan Murr and Robert Phillips, and any of their substitutes, signing singly, as the undersigned's true and lawful attorney-in-fact to:

- prepare, execute in the undersigned's name and on the undersigned's behalf, and submit to the U.S. Securities and Exchange Commission (the "SEC") a Form ID, including amendments thereto, and any other document necessary or appropriate to obtain codes, passwords, and passphrases enabling the undersigned to make electronic filings with the SEC of reports require by the Securities Exchange Act of 1934 or any rule or regulation of the SEC;
- 2. execute for and on behalf of the undersigned, in the undersigned's capacity as a director and/or officer of Cogent Biosciences Inc. (the "Company"), Forms 3, 4, and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934 and the rules thereunder;
- 3. do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form 3, 4, or 5, complete and execute any amendment or amendments thereto, and timely file such form with the SEC and any securities exchange or similar authority; and
- 4. take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-infact may approve in such attorney-in-fact's discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that each such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned also ratifies hereby any action previously taken by each attorney-in-fact that would have been authorized by this power of attorney if it has been in effect at the time such action was taken. The undersigned acknowledges that each attorney-in-fact, in serving in such capacity at the request of the undersigned, is not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934, as amended.

This Power of Attorney shall remain in full force and effect until the earliest to occur of (a) undersigned is no longer required to file Forms 3, 4, and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, (b) revocation by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact or (c) as to any attorney-in-fact individually, until such attorney-in-fact is no longer employed by the Company or its subsidiaries.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 6th day of April, 2021.

/s/ John Robinson John Robinson